Holding(s) in Company

RNS Number : 3018U

Mediclinic International plc

29 July 2022

 

Mediclinic International plc

(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic" , the " Company", or the "Group" )

29 July 2022

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B8HX8Z88

Issuer Name

MEDICLINIC INTERNATIONAL PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

JPMorgan Chase & Co.

City of registered office (if applicable)

Country of registered office (if applicable)

US

4. Details of the shareholder

Name	City of registered office	Country of registered office
J.P. Morgan Securities plc

5. Date on which the threshold was crossed or reached

27-Jul-2022

6. Date on which Issuer notified

29-Jul-2022

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	0.951405	6.162299	7.113704	52445759
Position of previous notification (if applicable)	0.949276	6.028796	6.978072

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00B8HX8Z88		7014177		0.951405
Sub Total 8.A	7014177		0.951405%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Cash-settled Equity Swap	23/11/2022	23/11/2022	Cash	25091493	3.403408
Cash-settled Equity Swap	04/01/2023	04/01/2023	Cash	137352	0.018629
Cash-settled Equity Swap	01/02/2023	01/02/2023	Cash	16152	0.002190
Cash-settled Equity Swap	22/02/2023	22/02/2023	Cash	44345	0.006012
Cash-settled Equity Swap	17/03/2023	17/03/2023	Cash	14682	0.001990
Cash-settled Equity Swap	30/05/2023	30/05/2023	Cash	99	0.000013
Cash-settled Equity Swap	02/06/2023	02/06/2023	Cash	12940451	1.755237
Cash-settled Equity Swap	04/07/2023	04/07/2023	Cash	6606429	0.896087
Cash-settled Equity Swap	12/07/2023	12/07/2023	Cash	24807	0.003360
Cash-settled Equity Swap	09/08/2023	09/08/2023	Cash	759	0.000102
Cash-settled Equity Swap	16/08/2023	16/08/2023	Cash	15000	0.002033
Cash-settled Equity Swap	21/08/2023	21/08/2023	Cash	585	0.000078
Cash-settled Equity Swap	22/08/2023	22/08/2023	Cash	598	0.000081
Cash-settled Equity Swap	19/01/2024	19/01/2024	Cash	44403	0.006021
Cash-settled Equity Swap	05/01/2027	05/01/2027	Cash	429053	0.058193
Cash-settled Equity Swap	06/07/2027	06/07/2027	Cash	93	0.000012
Cash-settled Equity Swap	09/07/2029	09/07/2029	Cash	65281	0.008853
Sub Total 8.B2				45431582	6.162299%

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
JPMorgan Chase & Co.	J.P. Morgan Securities plc		6.162299	6.162299%
JPMorgan Chase & Co.	JPMorgan Chase Bank, National Association
JPMorgan Chase & Co.	J.P. Morgan Equities South Africa Proprietary Limited
JPMorgan Chase & Co.	J.P. Morgan SE

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

Chain of controlled undertakings:

JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Securities plc (100%)

JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)

JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Equities South Africa Proprietary Limited (100%)

JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan SE (100%)

12. Date of Completion

29-Jul-2022

13. Place Of Completion

London

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case clinics and 22 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 22 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE

For further information, please contact:

Company Secretary, Link Company Matters Limited

Caroline Emmet

[phone]

Investor queries

James Arnold, Head of Investor Relations, Mediclinic International plc

[phone]

[e-mail]  

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address : 6 ^th  Floor, 65 Gresham Street, London, EC2V 7NQ, UK

Website:   www.mediclinic.com

Joint corporate brokers : Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa) : Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia) : Simonis Storm Securities (Pty) Ltd

 

END

 

 

HOLUKRURURUBUAR